Drugs / NTC-510A
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02161354 | Jun 2014 → Feb 2016 | dental pulp disorder | NanoSHIFT LLC | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NTC-510A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02161354 ↗ |
| Route | Oral | “NTC-510A or placebo will be given as a single oral dose of 2.0, 4.0, or 6 mg for acute pain relief (PR) following third molar extraction” NCT02161354 ↗ |